Whether complement activation plays a role in the therapeutic efficacy of unconjugated therapeutic monoclonal antibodies such as rituximab has been widely debated. In this issue of Blood, Wang and colleagues suggest that complement has an inhibitory effect on NK cell-mediated cytotoxicity in vitro and therapeutic monoclonal antibody efficacy in vivo.
No takes yet. Share an insight, caveat, or question.
Introna et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: